Introduction
Well-designed randomised controlled trials (RCTs) are considered the most trustworthy sources of evidence to guide clinical practice for questions of therapy and prevention. However, in order to provide high-quality evidence, RCTs need to employ well-defined methodological safeguards against bias (such as allocation concealment, blinding, and minimisation of loss-to-follow-up) and be transparently reported [1] . In addition, for trial results to be meaningful, they need to be sufficiently precise to establish a clinically relevant impact or to rule out such an impact. The reporting of CIs in conjunction with effect sizes are helpful in this context but are infrequently reported and not well understood [2, 3] . A methodological study of 'negative' trials (those that had failed to show superiority of the intervention over the control) found that approximately one-third of study authors misinterpreted non-significant study findings [4] .
To facilitate a clinician's appreciation of precision, which relates to sample size and more importantly, event rates, the Fragility Index was developed as a novel metric to assess the robustness of statistically significant results and complement P values and CIs [5] . Statistical significance implies that an observed, or more extreme result, is unlikely to occur by chance alone. The Fragility Index is defined as the minimum number of patients in a trial whose status would have to change from 'event' to 'non-event' to cause the P value to exceed 0.05 (the traditional threshold for statistical non-significance). Events refer to the occurrence of a dichotomous outcome, such as development of a UTI, clearance of stones after intrarenal surgery, or recurrence of continence after prostatectomy, and the Fragility Index can only be calculated in RCTs with such outcomes. A small Fragility Index indicates that the statistical significance of a particular trial hinges on only a few events, rendering the reported results as being 'more fragile', whilst a larger Fragility Index lends confidence to the observed treatment effects.
To date, the Fragility Index has not been utilised in urology, but it has been evaluated in the orthopaedic, critical care, neurosurgery, and cardiology literature, as well as amongst major trials published in high-impact general medical journals [5] [6] [7] [8] [9] [10] . We performed the present study to explore this novel metric and assess the fragility of RCTs published in the urological literature over a 5-year period.
Materials and Methods
We performed a literature search for the years 2011-2015, to identify all RCTs published in four major urology journals: BJU International, European Urology, Journal of Urology, and Urology. These journals were selected based on their relevance to general urology and use in previously published methodological studies [1, [11] [12] [13] . We included trials that were two parallel arm or two-by-two factorial design RCTs involving humans, which allocated participants in a 1:1 ratio to treatment and control, and which reported at least one dichotomous outcome as being statistically significant (P < 0.05). Two reviewers independently screened and identified abstracts. Data were abstracted using a standardised form from each trial, with data elements including the details of the statistically significant outcome (type of outcome, whether it was the primary study outcome, number of patients randomised to each group, number of patients who experienced an outcome in each group, and number of participants lost to follow-up by treatment arm). If a trial reported more than one significant result, only the first result or the result conferring to a dichotomous outcome was extracted.
The extracted data from each trial were represented in a twoby-two contingency table (Table 1 ) [5] . The Fragility Index was calculated in the same manner as reported by Walsh et al. [5] . In summary, an event was added to the group with the smaller number of events, while subtracting a non-event from the same group to keep the total number of patients constant. The Fisher's exact test was used to re-calculate a two-sided P value. Events were iteratively added until the first time the re-calculated P value became ≥0.05. The number of additional events required to obtain a P ≥ 0.05 was considered the trial's Fragility Index.
Summary descriptive statistics were then determined using the Statistical Package for the Social Sciences (SPSS â ), version 23 (SPSS Inc., IBM Corp., Armonk, NY, USA). We characterised the median Fragility Index amongst the trials identified, as well as a Pearson correlation statistic between Fragility Index and study sample size and event rate. Loss to follow-up affects both the number of study participants at risk, as well as potentially the number of recorded events. Therefore, we also examined the association of loss to followup and compared this to the Fragility Index for each included trial.
Results
We identified a total of 332 RCTs studies over the 5-year study period from 2011 to 2015. Amongst these, 41 were eligible for analysis after exclusions. The majority of studies were excluded because they primarily assessed nondichotomous outcomes, using time-to-event (e.g., overall survival), continuous (e.g., IPSS) or ordinal variables (e.g., Fuhrman grade). Table 2 lists the included RCTs, the year and journal of publication, the outcome considered, as well as the reported sample size, P value, and calculated Fragility Index. The median sample size (interquartile range [IQR]) was 99 (65, 179), whilst the median (IQR) event rate per study outcome was 38 (24, 65) . The median (IQR) Fragility Index was 3 (1, 4.5), indicating that the addition of only three alternate events to an arm of the average trial would have eliminated its statistical significance. Nine outcomes (22%) had a Fragility Index of zero because they lost their statistical significance when the P values were recalculated using the two-sided Fisher's exact test. There was a statistically significant correlation between the Fragility Index and events per study (q = 0.552, P = 0.01), as well as sample size (q = 0.493, P = 0.01). In 27/40 cases (67.5% of cases), the number of patients lost to follow-up was larger than its Fragility Index. One trial did not report loss of follow-up information.
Discussion

Principal Findings
The key finding of the present study is a notable fragility of the statistically significant outcomes amongst RCTs published in the urological literature; on average, as few as three additional events added to the trial arm deemed to be inferior would have eliminated its statistical significance. In two-thirds of these trials, the number of patients' lost-to follow-up was Table 1 Calculation of the Fragility Index. Adapted from Walsh et al. [5] .
Trial result
Calculated fragility
Fisher's exact test P ≥ 0.05
Fragility Index: The smallest value of 'f' that causes the Fisher's exact test P value to meet or exceed 0.05. equal to or greater than the calculated Fragility Index, thereby drawing the trial findings further into question. Of importance is that these findings are limited to those RCTs that were of two parallel arms or two-by-two factorial design, and which were reporting dichotomous outcomes.
Strengths and Weakness of the Study
Our present study stands out as the first of its kind to apply the novel measure of the Fragility Index to urological RCTs. The methodological approach, which includes duplicate data abstraction by two independent members of the research team, strengthens the validity of our findings. A major limitation of the present study is the small number of eligible included studies, which precluded further statistical analyses (e.g., subgroup analyses by clinical subspecialty or journal of publication). This is due to the relative infrequency with which urological RCTs report statistically significant dichotomous outcomes. Similarly, relatively straightforward methods for assessing continuous or time-to-event outcomes are not currently available. Consistent with prior studies that have sought to assess the methodological and reporting quality of RCTs, systematic reviews, and observational studies, our present study sample was limited to four major urology journals [1, 11, 55] . The present study therefore cannot speak to the large number of trials relevant to the practice of urology published in other medical journals, or to those evaluating continuous variables or which otherwise would fall outside of the scope of a Fragility Index calculation. The elimination of statistical significance in nine studies simply by re-calculating the P values using the Fisher's exact test also underscores the importance of selecting appropriate statistical tests and highlights how test selection itself can vary the perceived significance of reported findings.
Strengths and Weaknesses in Relation to Other Studies, Discussing Important Differences in Results
The Fragility Index is a novel metric and has been applied in only a few other studies, although it is gaining in popularity given several recent publications [5] [6] [7] [8] [9] [10] . An evaluation of RCTs published in high-impact medical journals found a median (range) Fragility Index of 8 (0-109), with 25% of individual trials having an index of ≤3. In 53% of studies, the Fragility Index was less than the number of patients lost to follow-up [5] . A similar study of the spine surgery literature found a median (IQR) Fragility Index of 2 (1-3). Similar to our present findings, the Fragility Index was less than or equal to the number of patients lost to follow-up in 65% of the trials [7] . A study of the sports medicine literature also reported a median (IQR) Fragility Index of 2 (1-2.8) [8] , as did a study of the critical care literature 2 (1-3.5) [6] . Each of these studies used very similar methods and therefore appears comparable. These findings would suggest that the fragility of RCTs published in the urology literature is slightly better than that of other subspecialties, but notably inferior to the fragility of trials published in high-impact medical journals.
Meaning of the Study: Possible Explanations and Implications for Clinicians and Policymakers
Statistical significance and P values should not be interpreted in isolation, as they provide only a snapshot of an overall study's merits. The statistical significance of some RCTs published in the urological literature hinges on very few events. This may represent one explanation for why similarly well-designed RCTs for the identical interventions sometimes provide conflicting results. This finding also underscores the importance of critically assessing the proportion of patients randomised yet not included in the final analysis for a given outcome, namely attrition bias. This may occur for a variety of reasons, including protocol deviations, withdrawal of consent, the occurrence of adverse events, or a combination thereof. The main underlying concern is that patients who are not included in the final analysis are systematically different from patients who are included in the analysis, thereby disrupting the prognostic balance of groups established at baseline through randomisation and allocation concealment. The implication of loss to follow-up is most important when the event rates in the trial are low and a few additional events in either arm could have a major impact on the trial results. A methodological study of 235 RCTs published from 2005 to 2007 in five top general medical journals found that the method by which loss to follow-up was handled was unclear in one out of five studies and up to one-third of studies lost statistical significance under plausible assumptions as to the incidence of events in those lost-to-follow-up [56] . Another relevant issue is that of stopping trials early for benefit, thereby lowering the number of overall events and resulting in a decreased precision of the results, as reflected in wider CIs [57] . While these are separate (yet related) issues to that of statistical fragility, they emphasise the careful attention clinicians, editors, and guideline developers should pay to seemingly minor methodological issues of clinical trial reporting.
Caution should be exercised to avoid misinterpretation of the Fragility Index. While a low Fragility Index indicates that the P value hinges on only few events, it is important to remember that the Fragility Index, and indeed P values themselves, are not measures of clinical effect. Carter et al. [58] reported in a simulated data set how the Fragility Index repackages the P value to correlate inversely with it. When the Fragility Index is low, it provides value as an intuitive metric to contextualise a study's results with respect to discontinuation or lost-to-follow-up rates. However, when the Fragility Index is high, like a low P value, it should not be confused with providing a measure of clinical strength of effect. While the concept of the P value to establish a 'threshold level of statistical significance' is convenient and broadly understood, there have been a number of limitations raised about over-reliance on P values, including the fact that P values do not allow for a nuanced understanding of effect size [59] . As noted, a P value of 0.001 compared with 0.04 does not signal a greater importance of the findings. Similarly, a Fragility Index of 10 should not be interpreted to imply greater clinical effect than a Fragility Index of 1; rather, it simply illustrates the strength of the statistical significance itself. A recent and very large survey of the medical literature using automated text mining analysis found a continued overemphasis on P values, which were nearly universally reported, but rarely complemented by effect estimates and measures of uncertainty, such as CIs [60] . We suggest that routinely reporting the Fragility Index may provide an easily understood and practical additional way of communicating the robustness of statistically significant findings to readers.
Unanswered Questions and Future Research
Further methodological research is required to determine whether a credible metric similar to the Fragility Index might be developed for studies with continuous variables, given than many urological RCTs are powered to detect differences in outcomes measured with scales or scoring systems rather than dichotomous events. Lastly, the research community should engage in a discourse as to what we might consider an acceptable level of fragility.
Conclusions
The results of urology RCTs that study dichotomous outcomes and report statistically significant differences between groups are sometimes fragile and depend on few events. Urologists should interpret these RCTs cautiously, particularly when the number of participants lost to follow-up exceeds the Fragility Index. Routine reporting of Fragility Index values alongside P values may provide additional guidance about the robustness of statistically significant findings in these types of studies.
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